文献速递银屑病与炎症性皮肤病

司库奇尤单抗治疗银屑病长达5年免疫原性低

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-06-20

本文报告两项3期延伸研究(NCT01640951和NCT01365455)中司库奇尤单抗治疗中重度斑块状银屑病长达5年的免疫原性。1821例患者进入延伸研究,1636例可评估抗药抗体(ADA),32例出现治疗中出现抗药抗体(TE-ADA),年新发TE-ADA率低于1%,且TE-ADA(包括中和抗体)与疗效、安全性或药代动力学无关。

要点

  • 司库奇尤单抗治疗5年内年免疫原性发生率持续低于1%。
  • 32例TE-ADA中9例(28%)检测到中和抗体,半数ADA阳性为一过性。
  • TE-ADA(包括中和抗体)未影响疗效、安全性或药代动力学。

核心结论

  • 司库奇尤单抗治疗中重度斑块状银屑病5年内年免疫原性发生率持续低于1%。
  • 任何TE-ADA(包括中和抗体)均与司库奇尤单抗疗效丧失或临床担忧无关。

研究设计与样本

  • 两项3期延伸研究(NCT01640951和NCT01365455)评估司库奇尤单抗治疗中重度斑块状银屑病长达5年的免疫原性。
  • 共1821例患者进入延伸研究,其中1636例接受司库奇尤单抗并评估抗药抗体(ADA)。

主要发现

  • 1636例可评估患者中32例出现TE-ADA,年新发TE-ADA病例发生率低于1%。
  • 32例TE-ADA患者中9例(28%)检测到中和抗体,半数ADA阳性病例为一过性。
  • 在免疫原性测定时采集的药代动力学样本(n=9992)中,544份(5.4%)司库奇尤单抗浓度高于药物耐受水平53.8 μg/mL。
  • TE-ADA(包括中和抗体)对司库奇尤单抗的疗效、安全性或药代动力学无影响。

关键数值与推荐

  • TE-ADA定义为基线信号阴性患者治疗后样本中检测到阳性抗药抗体(ADA)信号。
  • 确认阳性样本进一步分析其中和潜力。
  • 免疫原性评估长达第268周(5年)。

临床怎么用

  • 长期使用司库奇尤单抗时免疫原性风险低,无需常规监测抗药抗体。
  • 出现疗效下降时,TE-ADA(包括中和抗体)不太可能是原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, a key cytokine involved in psoriasis and psoriatic arthritis development, and has shown rapid and long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations. Monoclonal antibody therapies may be associated with the production of treatment-emergent antidrug antibodies (TE-ADAs) that can affect drug pharmacokinetics, diminish clinical responses via inhibition of target binding or cause hypersensitivity reactions. Secukinumab exhibited minimal immunogenicity up to 52 weeks in patients with moderate-to-severe plaque psoriasis, as evidenced by TE-ADA in <1% patients. OBJECTIVE: To investigate the immunogenicity of secukinumab treatment up to 5 years in two phase 3 extension studies (NCT01640951 and NCT01365455) in patients with moderate-to-severe plaque psoriasis. METHODS: Immunogenicity was evaluated up to Week 268 (5 years). TE-ADAs were defined as positive antidrug antibody (ADA) signals detected in post-treatment samples from patients with negative baseline signals. Confirmed positive samples were further analysed for their neutralizing potential. RESULTS: In total, 1821 patients entered the extension studies. Among patients receiving secukinumab and evaluated for ADAs (n = 1636), 32 developed TE-ADA, which resulted in an incidence of new TE-ADA cases below 1% per year. Neutralizing antibodies were detected in 9/32 (28%) patients with TE-ADA. Half of ADA-positive cases were transient. Among pharmacokinetic samples measured at the times of immunogenicity determination (n = 9992), 544 (5.4%) had secukinumab concentrations higher than the drug tolerance level of 53.8 μg/mL. There was no effect of TE-ADA, including neutralizing antibodies, on efficacy, safety or pharmacokinetics of secukinumab. CONCLUSION: The yearly secukinumab immunogenicity incidence over 5 years of treatment was consistently below 1% in patients with moderate-to-severe plaque psoriasis. Any TE-ADAs, including neutralizing antibodies, were not associated with loss of secukinumab efficacy or with clinical concerns.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Reich K, Blauvelt A, Armstrong A, et al. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. J Eur Acad Dermatol Venereol. 2019. PMID: 31009130. doi:10.1111/jdv.15637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。